Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD5024 1% cream in adult acne vulgaris
2016-000063-16Phase 2Completed
- Sponsor
- Galderma
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of ivermectin in acne vulgaris (2 arms), sponsored by Galderma. Primary endpoint: Inflammatory acne lesion count per half face. Started Mar 2016; status: completed.
02
Drugs
ivermectin
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on 2016-000063-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000063-16.